Detroit, MICHIGAN11 Active Studies

Osteogenesis Imperfecta Clinical Trials in Detroit, MICHIGAN

Find 11 actively recruiting osteogenesis imperfecta clinical trials in Detroit, MICHIGAN. Connect with local research sites and explore new treatment options.

11
Active Trials
11
Sponsors
1,630
Enrolling

Recruiting Osteogenesis Imperfecta Studies in Detroit

RecruitingDetroit, MICHIGANNCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

366 participants
Priothera SAS
View Study Details
RecruitingDetroit, MICHIGANNCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

To evaluate the long-term safety and tolerability of oral dersimelagon....

301 participants
Mitsubishi Tanabe Pharma America Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT06292780

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need...

220 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingDetroit, MICHIGANNCT06910358

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin incre...

150 participants
Disc Medicine, Inc
View Study Details
RecruitingDetroit, MICHIGANNCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with ca...

141 participants
Crinetics Pharmaceuticals Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT05143840

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...

100 participants
Augusta University
View Study Details
RecruitingDetroit, MICHIGANNCT05890729

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis...

94 participants
Xentria, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT07081646

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis....

91 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT06456463

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azaci...

76 participants
Stemline Therapeutics, Inc.
View Study Details
RecruitingDetroit, MICHIGANNCT04838041

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have...

51 participants
Medical College of Wisconsin
View Study Details
RecruitingDetroit, MICHIGANNCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....

40 participants
Nexcella Inc.
View Study Details

About Osteogenesis Imperfecta Clinical Trials in Detroit

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 11 osteogenesis imperfecta clinical trials recruiting participants in Detroit, MICHIGAN. These studies are seeking a combined 1,630 participants. Research is being sponsored by Priothera SAS, Mitsubishi Tanabe Pharma America Inc., Regeneron Pharmaceuticals and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Detroit — FAQ

Are there osteogenesis imperfecta clinical trials in Detroit?

Yes, there are 11 osteogenesis imperfecta clinical trials currently recruiting in Detroit, MICHIGAN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Detroit?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.

Are clinical trials in Detroit free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 11 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated March 2, 2026 from ClinicalTrials.gov